Skip to main content
Smart Investors Daily
Bionano Genomics, Inc. logo

NYSE · BNGO

Bionano Genomics, Inc.

Healthcare · Medical - Diagnostics & Research

$0.89

Down-$0.09 (-9.31%)

Updated Nov 20, 2026, 2:01 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.48M
P/E ratio
-0.23
Dividend yield
0.00%
52-week range
$0.93 – $2.23
Volume
261.6K
Avg. volume
721.42K

Price performance · BNGO

BNGO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

BNGO closed at $0.89 after 21 trading sessions, down 25.00% for the selected period.

Last close
$0.89
Period change
-25.00%
Period low
$0.89
Period high
$1.23
Daily close
View OHLC price history
BNGO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$0.9862$0.99$0.8737$0.885261.6K
Nov 18, 2026$0.9578$0.99$0.9578$0.975968.38K
Nov 17, 2026$0.951$0.9699$0.946$0.952172.85K
Nov 16, 2026$1.00$1.0001$0.9285$0.94253.65K
Nov 13, 2026$1.02$1.03$1.00$1.00557.57K
Nov 12, 2026$1.12$1.12$0.97$1.04835.84K
Nov 11, 2026$1.17$1.30$1.09$1.10583.84K
Nov 10, 2026$1.16$1.35$1.16$1.23568.04K
Nov 9, 2026$1.14$1.195$1.122$1.16149.28K
Nov 6, 2026$1.13$1.15$1.10$1.1597.02K
Nov 5, 2026$1.19$1.19$1.0701$1.10394.39K
Nov 4, 2026$1.21$1.22$1.18$1.1972.18K
Nov 3, 2026$1.16$1.20$1.16$1.20130.92K
Nov 2, 2026$1.17$1.1898$1.14$1.1689.12K
Oct 30, 2026$1.18$1.20$1.12$1.15196.43K
Oct 29, 2026$1.20$1.205$1.18$1.2067.19K
Oct 28, 2026$1.23$1.25$1.195$1.205114.37K
Oct 27, 2026$1.19$1.22$1.15$1.2273.59K
Oct 26, 2026$1.15$1.165$1.135$1.1662.37K
Oct 23, 2026$1.18$1.18$1.10$1.13251.96K
Oct 22, 2026$1.26$1.2997$1.17$1.18443.18K

Latest BNGO news

The latest Smart Investors Daily articles mentioning BNGO.

BNGO research

Overview

Company profile and research snapshot.

Company profile

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$46.50
Implied upside
—
Analysts
—
BNGO recent ratings
DateFirmRatingTarget
Apr 13, 2026HC Wainwright & Co.Buy—
Nov 24, 2025HC Wainwright & Co.Buy—
Aug 18, 2025HC Wainwright & Co.Buy—
May 20, 2025Maxim GroupBuy—
Apr 9, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Bionano Reports Third Quarter 2026 Results and Provides a Business Update

Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2026. “Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings,” commented Al Luderer, Ph.D., chairman and interim chief executi

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.